View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 17, 2022

Junshi doses first subject in Phase III Covid-19 drug trial in China

The percentage of subjects who advance to critical/severe disease or mortality within 29 days is the trial’s primary endpoint.

Shanghai Junshi Biosciences has dosed the first subject in the Phase III clinical trial of an investigational drug, VV116, to treat moderate-to-severe Covid-19. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An oral nucleoside analog anti-SARS-CoV-2 drug, VV116 is designed to hinder virus replication. 

It is co-developed by Junshi along with Vigonvita Life Sciences.

In preclinical studies, VV116 demonstrated substantial anti-SARS-CoV-2 effects in vivo and in vitro, had increased oral bioavailability and good chemical stability.

Furthermore, the drug demonstrated to possess antiviral activity against original viral strain and key variants including Alpha, Beta, Delta and Omicron.

The global, double-blind, multicentre, randomised, controlled trial will analyse the safety and efficacy of VV116 versus standard treatment in moderate to severe Covid-19 patients. 

The percentage of subjects who advance to critical/severe Covid-19 or all-cause mortality within 29 days is the primary endpoint of the trial.

Apart from this Phase III trial, Junshi and Vigonvita commenced a global, double-blind, multicentre, randomised, placebo-controlled Phase II/III trial of VV116 in subjects with mild-to-moderate Covid-19. 

This Phase II/III trial which has currently enrolled and dosed the first participant in China, will assess the safety, efficacy and pharmacokinetics of VV116 as an early treatment for mild to moderate disease.

It has a primary endpoint identical to the Phase III trial.

According to initial data from three concluded Phase I trials analysing the safety, tolerability and pharmacokinetics of VV116 in healthy Chinese participants, the drug demonstrated to have favourable clinical safety. 

Findings from a Phase II trial of VV116 in Uzbekistan last year showed that two varying doses of the drug were found to have encouraging safety in moderate and severe Covid-19 patients versus standard treatment. 

Based on these data, VV116 obtained approval in Uzbekistan last year to treat patients with moderate to severe Covid-19.

In June 2020, Junshi dosed the first healthy subject in the Phase I trial of JS016, its SARS-CoV-2 neutralising antibody.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena